kiki's statement is absolutely correct!!!
I don't know what you consider "agitprop" (I assume it's not bio.rese's daily offerings, LOL).
You might want to look at some of the papers at ASH if you don't think:
1. Iclusing IS an effective (the most effective by far) drug
2. That efforts are underway to make the risk/benefit ratio more favorable.
Maybe the selection committee at ASH doesn't recognize "agitprop".
Point one is beyond dispute (and again, remember, that the risk with
Gleevec and 2nd line drugs is a relapse in a vicious disease, leaving
the patient in a very precarious position. Yes, Iclusig to the rescue but
I would chose to go with Iclusig in the first place, and hope that I'm in
the 93 percent with no SAE's (a number that will improve over time).
Point two has been obvious to anyone with a little familiarity with the
way docs in the frontline of terrible diseases operate,.... they do whatever
is necessary to save their patients! Given Iclusig's efficacy, that work
(to reduce side effects) is even more compelling.
As far as Suisse/Kantor's downgrade, just read it and you'll see the
dishonesty jumping out. Not only ignoring the real possibility (probability
in my view) of increased use of Iclusig (why?.. see points 1 and 2 above)
BUT, ignoring all positive factors that could and most likely will push
the pps upward (partnerships, pona in other indications, progress with
113 toward approval and BIC recognition, new molecule). I rate Kantor
a D for Dishonest!
News 
Market Data 
Discover 
AI
